📊 RARE Key Takeaways
Is Ultragenyx Pharmaceutical Inc. (RARE) a Good Investment?
Ultragenyx faces critical solvency concerns with negative stockholders equity of -$236M and annual free cash flow of -$198M, implying ~11 months of cash runway at current burn rates. Despite 20.2% YoY revenue growth, the company's operating margin of -124% demonstrates severe unprofitability, suggesting underlying business model challenges rather than early-stage development delays.
Ultragenyx Pharmaceutical Inc. Key Strengths (RARE)
- Revenue growing 20.2% YoY demonstrates market demand and product traction
- Cash position of $175M provides near-term operational continuity
- Current ratio of 2.02x indicates ability to cover short-term liabilities
- Significant insider trading activity (20 Form 4 filings) in past 90 days
RARE Stock Risks: Ultragenyx Pharmaceutical Inc. Investment Risks
- Negative stockholders equity of -$236M indicates technical insolvency; liabilities exceed assets by $200M+
- Cash burn of $198M annually creates existential runway of approximately 11 months without financing
- Operating losses of $169M on $136M revenue reveal inability to monetize revenue base or control costs
- Company will require dilutive capital raise; likely to impair existing shareholder value materially
Key Metrics to Watch
- Monthly cash burn trend and operating cash flow - determines survival timeline
- Revenue per dollar of operating expense - indicator of path to profitability
- Capital raise announcements and terms - will signal shareholder dilution magnitude
- Gross margin evolution on product revenue - reveals pricing power and unit economics
Ultragenyx Pharmaceutical Inc. (RARE) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.02x current ratio provides a solid financial cushion.
RARE Profit Margin, ROE & Profitability Analysis
RARE vs Healthcare Sector: How Ultragenyx Pharmaceutical Inc. Compares
How Ultragenyx Pharmaceutical Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Ultragenyx Pharmaceutical Inc. Stock Overvalued? RARE Valuation Analysis 2026
Based on fundamental analysis, Ultragenyx Pharmaceutical Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Ultragenyx Pharmaceutical Inc. Balance Sheet: RARE Debt, Cash & Liquidity
RARE Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Ultragenyx Pharmaceutical Inc.'s revenue has grown significantly by 92% over the 5-year period, indicating strong business expansion. The most recent EPS of $-8.25 indicates the company is currently unprofitable.
RARE Revenue Growth, EPS Growth & YoY Performance
RARE Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $136.0M | -$151.0M | $-1.57 |
| Q3 2025 | $139.5M | -$133.5M | $-1.40 |
| Q2 2025 | $147.0M | -$115.0M | $-1.17 |
| Q1 2025 | $108.8M | -$151.1M | $-1.57 |
| Q3 2024 | $98.1M | -$133.5M | $-1.40 |
| Q2 2024 | $108.3M | -$131.6M | $-1.52 |
| Q1 2024 | $100.5M | -$164.0M | $-2.03 |
| Q3 2023 | $90.7M | -$159.6M | $-2.23 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Ultragenyx Pharmaceutical Inc. Dividends, Buybacks & Capital Allocation
RARE SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Ultragenyx Pharmaceutical Inc. (CIK: 0001515673)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RARE
What is the AI rating for RARE?
Ultragenyx Pharmaceutical Inc. (RARE) has an AI grade of C with 87% confidence, based on fundamental analysis of SEC EDGAR filings.
What are RARE's key strengths?
Claude: Revenue growing 20.2% YoY demonstrates market demand and product traction. Cash position of $175M provides near-term operational continuity.
What are the risks of investing in RARE?
Claude: Negative stockholders equity of -$236M indicates technical insolvency; liabilities exceed assets by $200M+. Cash burn of $198M annually creates existential runway of approximately 11 months without financing.
What is RARE's revenue and growth?
Ultragenyx Pharmaceutical Inc. reported revenue of $136.0M.
Does RARE pay dividends?
Ultragenyx Pharmaceutical Inc. pays dividends, with $4.3M distributed to shareholders in the trailing twelve months.
Where can I find RARE SEC filings?
Official SEC filings for Ultragenyx Pharmaceutical Inc. (CIK: 0001515673) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RARE's EPS?
Ultragenyx Pharmaceutical Inc. has a diluted EPS of $-1.84.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is RARE's fundamental grade?
Based on our AI fundamental analysis in May 2026, Ultragenyx Pharmaceutical Inc. has a C grade with 87% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is RARE stock overvalued or undervalued?
Valuation metrics for RARE: ROE of N/A (sector avg: 15%), net margin of -136.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is RARE's AI grade for 2026?
Our dual AI analysis gives Ultragenyx Pharmaceutical Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RARE's free cash flow?
Ultragenyx Pharmaceutical Inc.'s operating cash flow is $-197.0M, with capital expenditures of $1.0M. FCF margin is -145.6%.
How does RARE compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -136.0% (avg: 12%), ROE N/A (avg: 15%), current ratio 2.02 (avg: 2).